856693-04-4
Chemical Structure
CEP-14513
- CAS No.: 856693-04-4
- Formula:C34H36N6O3
- Molecular Weight:576.70
IUPAC Name: 13-isobutyl-4-methyl-6-oxo-2,4,6,7,8,13-hexahydro-1H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-10-yl (4-(dimethylamino)benzyl)carbamate
InChIKey: ZFKJDNACAGAYFJ-UHFFFAOYSA-N
SMILES: O=C(OC1=CC=C2C(=C1)C=3C(=C4C(C5=CN(N=C5CC4)C)=C6C(=O)NCC63)N2CC(C)C)NCC7=CC=C(C=C7)N(C)C
Biological Activity: CEP-14513 is an ALK inhibitor with an IC50 of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, TIE2 and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CEP-14513 | CEP-14513 is an ALK inhibitor with an IC50 of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, TIE2 and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
[1]. Puig de la Bellacasa R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013 Apr;2(2):72-86.
[Content Brief] - [2]. Gunby RH, et al. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. Anticancer Agents Med Chem. 2007;7(6):594-611. [Content Brief]
Keywords
